Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...
SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics” or "Rani”) (Nasdaq: ...
Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...
Hosted on MSN2d
What Role Do Peptides Play in Weight Loss?These hormones have several functions. For example, they: In people with type 2 diabetes, incretin levels are absent or lower than they should be. Peptide medications, like GLP-1 and GLP-1/GIP ...
Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...
Some of the “anti-ageing” benefits seen with GLP1RAs may simply be the result of their weight-loss inducing properties.
Reduction in body weight can prevent, delay or reduce the development of these conditions with advancing age. GLP-1RAs, ...
While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback